DK0790246T3 - Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf - Google Patents

Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf

Info

Publication number
DK0790246T3
DK0790246T3 DK95934859T DK95934859T DK0790246T3 DK 0790246 T3 DK0790246 T3 DK 0790246T3 DK 95934859 T DK95934859 T DK 95934859T DK 95934859 T DK95934859 T DK 95934859T DK 0790246 T3 DK0790246 T3 DK 0790246T3
Authority
DK
Denmark
Prior art keywords
salt
agent
growth factor
nerve growth
factor activity
Prior art date
Application number
DK95934859T
Other languages
English (en)
Inventor
Satoshi Ono
Mutsuko Maekawa
Kazunari Hirata
Hirokazu Narita
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP6284273A external-priority patent/JPH08268883A/ja
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of DK0790246T3 publication Critical patent/DK0790246T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK95934859T 1994-10-25 1995-10-20 Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf DK0790246T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP6284273A JPH08268883A (ja) 1994-10-25 1994-10-25 1−フェニル−1,2−エタンジオール誘導体またはそ の塩を含有する神経成長因子の作用増強剤
JP28427294 1994-10-25
PCT/JP1995/002162 WO1996012717A1 (en) 1994-10-25 1995-10-20 Potentiator for nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof

Publications (1)

Publication Number Publication Date
DK0790246T3 true DK0790246T3 (da) 2002-03-18

Family

ID=26555404

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95934859T DK0790246T3 (da) 1994-10-25 1995-10-20 Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf
DK00100580T DK1020427T3 (da) 1994-10-25 1995-10-20 Middel til at potensere nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivater eller salte deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00100580T DK1020427T3 (da) 1994-10-25 1995-10-20 Middel til at potensere nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivater eller salte deraf

Country Status (16)

Country Link
US (6) US5807887A (da)
EP (3) EP1223169A1 (da)
JP (1) JP3218247B2 (da)
KR (1) KR100447738B1 (da)
AU (1) AU700561B2 (da)
CA (1) CA2202032C (da)
CZ (1) CZ293528B6 (da)
DE (2) DE69525063T2 (da)
DK (2) DK0790246T3 (da)
ES (2) ES2208156T3 (da)
HU (1) HU226980B1 (da)
NZ (1) NZ294328A (da)
PL (2) PL187490B1 (da)
RO (1) RO119196B1 (da)
TW (1) TW341570B (da)
WO (1) WO1996012717A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0790246T3 (da) * 1994-10-25 2002-03-18 Toyama Chemical Co Ltd Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf
AU2576797A (en) * 1996-04-22 1997-11-12 Toyama Chemical Co. Ltd. Patch containing 1,2-ethanediol derivatives or salts thereof
WO1999031056A1 (en) * 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
JP4549452B2 (ja) * 1997-12-12 2010-09-22 富山化学工業株式会社 アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
PL196773B1 (pl) * 1999-06-11 2008-01-31 Toyama Chemical Co Ltd Pochodna N-alkiloksyalkilo-N,N-dialkiloaminy lub jej sole oraz środek zawierający ten związek stosowany do leczenia chorób neurodegeneratywnych
AU9235101A (en) * 2000-10-10 2002-04-22 Toyama Chemical Co Ltd Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof
CA2464358C (en) * 2001-10-19 2011-05-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or their salts
KR100935615B1 (ko) 2002-06-14 2010-01-07 토야마 케미칼 컴퍼니 리미티드 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
EP2068866A4 (en) 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894058A (en) * 1974-05-17 1975-07-08 Hoechst Co American Tetrahydrobenzofuranylphenoxypropylamines
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
NZ232493A (en) * 1989-02-14 1992-06-25 Toyama Chemical Co Ltd Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions
US5280032A (en) * 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP3044055B2 (ja) * 1990-08-09 2000-05-22 富山化学工業株式会社 1,2―エタンジオール誘導体およびその塩
JPH05230103A (ja) * 1992-02-18 1993-09-07 Taisho Pharmaceut Co Ltd ガングリオシド化合物
DK0790246T3 (da) * 1994-10-25 2002-03-18 Toyama Chemical Co Ltd Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf

Also Published As

Publication number Publication date
DE69531877D1 (de) 2003-11-06
AU3709795A (en) 1996-05-15
DE69525063D1 (de) 2002-02-21
EP1020427B1 (en) 2003-10-01
CZ293528B6 (cs) 2004-05-12
TW341570B (en) 1998-10-01
CZ124997A3 (en) 1997-10-15
EP1223169A1 (en) 2002-07-17
NZ294328A (en) 1998-06-26
CA2202032A1 (en) 1996-05-02
EP0790246A1 (en) 1997-08-20
PL187004B1 (pl) 2004-04-30
KR970707114A (ko) 1997-12-01
KR100447738B1 (ko) 2005-09-20
EP1020427A1 (en) 2000-07-19
CA2202032C (en) 2009-06-16
JP3218247B2 (ja) 2001-10-15
EP0790246A4 (en) 1998-03-11
US6034119A (en) 2000-03-07
AU700561B2 (en) 1999-01-07
PL319940A1 (en) 1997-09-01
PL187490B1 (pl) 2004-07-30
ES2208156T3 (es) 2004-06-16
HU226980B1 (en) 2010-04-28
DE69531877T2 (de) 2004-07-29
WO1996012717A1 (en) 1996-05-02
US5922721A (en) 1999-07-13
US5968935A (en) 1999-10-19
US5807887A (en) 1998-09-15
RO119196B1 (ro) 2004-05-28
EP0790246B1 (en) 2002-01-16
US5932620A (en) 1999-08-03
DE69525063T2 (de) 2002-08-14
DK1020427T3 (da) 2004-02-09
ES2171559T3 (es) 2002-09-16
HUT77361A (hu) 1998-03-30
US6103754A (en) 2000-08-15

Similar Documents

Publication Publication Date Title
FI963566A0 (fi) Uusia piperatsiinijohdoksia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä koostumuksia
FI965020A7 (fi) Uusia yhdisteitä, menetelmiä niiden valmistamiseksi ja kasvaintenvastaisia aineita
EE9600123A (et) 4,4-difluorobut-3-enüültio)-rühmaga asendatud heterotsüklilised või karbotsüklilised pestitsiidse aktiivsusega ühendid
FI932200L (fi) Foer hudrengoering avsedd mild toalettbit, som innehaoller foer huden milt/fuktgivande silikonhjaelpmedel
FI972646A0 (fi) Piperatsiinijohdannaiset, näitä yhdisteitä sisältävät lääkeaineet, niiden käyttö ja menetelmä niiden valmistamiseksi
DK1020427T3 (da) Middel til at potensere nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivater eller salte deraf
DK0742715T3 (da) Orale, væskeformige præparater indeholdende paroxetin-resinat
EP0671911A4 (en) CARBOXYPEPTIDYL DERIVATIVES AS AN ANTIDEGENERATIVE ACTIVE SUBSTANCES.
FI972308L (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
NO903863D0 (no) Tiazolidindionderivater som hypoglykemiske midler.
ES295930Y (es) Cornisa perfeccionada para obras de arte.
KR950701336A (ko) 퀴놀린 유도체 또는 그의 염, 및 이를 함유하는 심질환 치료제
FI951631L (fi) Substituoituja kynureniinejä, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä
FI972306L (fi) Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DK0782575T3 (da) Substituerede pyrazol-pyrazol-derivater, fremgangsmåde til deres fremsstilling samt deres anvendelse som midler med herbicid virkning
NO960272L (no) Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme
FI945164A7 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
DK0763535T3 (da) Piperidinylmethyloxazolidin-2-on-derivater, deres fremstilling og deres anvendelse som centralnervesystem-aktive forbindelser
FI972624A0 (fi) 14alfa,17alfa-C2-sillan sisältäviä 19-norprogesteronijohdoksia
ZA958991B (en) Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof
BR8902181A (pt) Derivado de sultamsulfonamida,compostos intermediarios para o mesmo e composicao herbicida
DE69116003D1 (de) Zusammensetzung, welche salz enfernt
FI950101A0 (fi) 4-oksa-1-atsabisyklo 3,2,0 -7heptanoni-johdannaiset kasvainten vastaisina aineina
NO912109L (no) Anti-mikrobielt middel.
EE03179B1 (et) Asendatud 2-propanooli derivaadid, neid sisaldavad farmatseutilised segud ja nende valmistamise protsessid